Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES TSXV APPROVAL OF DEBT SETTLEMENT AT $0.20 PER SHARE

Hemostemix Inc. has entered into agreements to settle an aggregate of $400,000 of indebtedness through the issuance of common shares of the company.

Pursuant to the debt settlement, the company will issue an aggregate of two million common shares at a deemed price of 20 cents per settlement share to certain creditors of the company. The settlement shares will be subject to a statutory hold period of four months and one day in accordance with applicable securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

The debt settlement is subject to acceptance by the TSX Venture Exchange and will be completed pursuant to TSX Venture Exchange Policy 4.3 (Shares for Debt).

The debt settlement will not result in the creation of a new control person. No finders' fees will be paid in connection with the debt settlement.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.